Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 3/20 | 0.37 |
| ▸ | FNTB | P49356 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | SQLE | Q14534 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CBLB | Q13191 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14826009 | 1.00 | KMT2A (0.38) | KMT2AKDM4EATMFNTAFNTB | |
| SCHEMBL14825983 | 1.00 | KMT2A (0.38) | KMT2AKDM4EATMFNTAFNTB | |
| SCHEMBL9927425 | 0.89 | ALDH1A1 (0.36) | KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL3637902 | 0.88 | ALDH1A1 (0.38) | KMT2AALDH1A1MEN1 | |
| SCHEMBL14827709 | 0.85 | KMT2A (0.53) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL14827685 | 0.85 | KMT2A (0.53) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL16706215 | 0.83 | KMT2A (0.38) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL14827686 | 0.83 | KMT2A (0.38) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL14853097 | 0.83 | KMT2A (0.38) | KMT2AKDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL14826004 | 0.83 | TRPV1 (0.35) | KDM4EATMKDM1APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| WO-2014163643-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275281-A1 | Geranylgeranyl acetone and derivatives thereof for intranasal administration | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275281-A1 | Geranylgeranyl acetone and derivatives thereof for intranasal administration | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275091-A1 | Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275091-A1 | Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275282-A1 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275282-A1 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013052148-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | KMT2A 3588/4885KDM4E 3078/4885ATM 3678/4885 |
| US-20140275281-A1 | Geranylgeranyl acetone and derivatives thereof for intranasal administration | GGPS1, NAA50, GAP43 | KMT2A 4492/4885KDM4E 4689/4885ATM 2450/4885 |
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | GGPS1, EBP, GGCT | KMT2A 3946/4885KDM4E 3424/4885ATM 800/4885 |
| US-20140275091-A1 | Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery | FNTA, GGPS1, GNPAT | KMT2A 4488/4885KDM4E 4505/4885ATM 4441/4885 |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | UGP2, TGM2, GGCT | KMT2A 2968/4885KDM4E 3382/4885ATM 3739/4885 |
| US-20140275282-A1 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof | GGPS1, EBP, GGCT | KMT2A 3946/4885KDM4E 3424/4885ATM 800/4885 |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | KMT2A 3588/4885KDM4E 3078/4885ATM 3678/4885 |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | GGPS1, FNTA, GNPAT | KMT2A 4082/4885KDM4E 4535/4885ATM 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.